Jacobio Pharmaceuticals Group Co., Ltd. Announces Intention to Repurchase Shares On-Market
Key Highlights for Investors:
- On-market share repurchase plan: Jacobio Pharmaceuticals Group Co., Ltd. (Stock Code: 1167) has announced its intention to repurchase up to 78,372,528 shares, representing up to 10% of the total number of issued shares, under a general repurchase mandate approved at the company’s AGM on June 5, 2026.
- Maximum allocation: The company will allocate up to HK\$100 million to these repurchases, which will be funded from its own financial resources rather than proceeds from its Hong Kong listing.
- Repurchase timing and discretion: The board has full discretion regarding the timing, quantity, and price of repurchases, which will be subject to market conditions. There is no guarantee on when or whether repurchases will occur.
- Price limit: Each repurchase price must not exceed 5% above the average closing market price for the shares over the preceding five trading days.
- Regulatory compliance: All repurchases will be conducted in accordance with the company’s articles, Hong Kong Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, Cayman Islands law, and all other applicable regulations.
- Potential share cancellation or treasury holding: Shares repurchased may be cancelled or held in treasury.
- Public float maintenance: Repurchases will not reduce the public float below the minimum required by the Hong Kong Stock Exchange.
Strategic Rationale and Implications for Shareholders
Jacobio’s board explicitly states that the current trading price does not adequately reflect the company’s intrinsic value, citing its robust pipeline in anti-tumour targeted therapies, ongoing global clinical trials, strong external partnerships, and a healthy cash position. The company stresses that its business operations and development are proceeding smoothly, with timely receipt of collaboration payments, ensuring ample liquidity.
The board views the proposed share buyback as a prudent and effective capital management measure, underpinned by the company’s long-term fundamentals and growth prospects. The board’s willingness to deploy internal resources for the repurchase signals a vote of confidence in Jacobio’s R&D pipeline and commercialisation potential.
Potential Price Sensitivity and Shareholder Considerations
- This announcement is potentially price sensitive. Share repurchases may support the share price by reducing supply and signaling management’s positive outlook for the company’s value.
- The actual impact on the share price will depend on the timing, size, and market perception of the repurchases.
- There is no certainty regarding the quantity or timing of repurchases, or if any repurchases will occur at all. The plan is subject to absolute board discretion and prevailing market conditions.
- Shareholders and potential investors are urged to exercise caution when dealing in the company’s securities due to the discretionary and opportunistic nature of the buyback plan.
Board Composition
The company’s board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU, and Dr. Ge WU as independent non-executive Directors.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should closely monitor official company announcements and consider their own circumstances or seek professional advice before making any investment decisions. The share repurchase is subject to market conditions and company discretion, and there is no guarantee that any repurchase will take place.
集寶醫藥集團股份有限公司宣佈擬於市場上回購股份——投資者詳盡資訊
投資者重點摘要：
- 市場回購股份計劃： 集寶醫藥集團股份有限公司（股份代號：1167）宣佈，根據2026年6月5日股東周年大會批准的一般回購授權，擬回購最多78,372,528股股份，佔已發行股份總數之10%。
- 最高資金撥備： 公司將動用最多1億港元於本次股份回購，資金來自公司自有財政資源，而非上市集資所得。
- 回購時間及酌情權： 董事會可全權決定回購的時間、數量及價格，視乎市況而定，並不保證何時或是否會進行回購。
- 價格上限： 每次回購價格不得高於前五個交易日平均收市價的5%。
- 合規性： 所有回購將遵守公司章程、香港聯交所上市規則、收購及合併及股份回購守則、開曼群島公司法及其他相關法例。
- 股份處理： 回購股份可註銷或存作庫藏股份。
- 維持公眾持股量： 回購不會導致公眾持股量低於聯交所最低規定。
策略原因及對股東的啟示
董事會明確指出，公司現時股價未能合理反映其內在價值，原因包括：抗腫瘤靶向治療藥物研發管線強勁、全球臨床試驗進展順利、對外合作持續、現金流充裕等。公司的業務發展及日常運作良好，合作付款亦能及時收取，現金流充足。
董事會認為，建議回購股份是審慎且有效的資本管理舉措，體現公司基本面和長遠價值，並反映管理層對研發管線及中長期增長的信心。
潛在價格敏感及股東注意事項
- 本公告屬潛在價格敏感信息。股份回購有機會支持股價，亦可釋放管理層對公司價值的信心。
- 實際對股價的影響將視乎回購的時間、規模及市場反應。
- 回購計劃是否實施、數量及時間並無保證，一切由董事會全權酌情及視乎市況。
- 股東及潛在投資者應審慎處理公司證券，因回購計劃具有機遇性及酌情性。
董事會組成
公司董事會成員包括：王印祥博士（主席及執行董事）、王曉潔女士及胡雲燕女士（執行董事）、陳特立博士（非執行董事）、宋瑞霖博士、呂白博士及吳戈博士（獨立非執行董事）。
免責聲明：本文僅供參考，並不構成任何投資建議。投資者應密切留意公司官方公告，並考慮自身情況或尋求專業意見，方作投資決定。本次股份回購視乎市況及公司酌情權，並不保證一定會進行。
